Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 10Specimen Handling 8Magnetic Resonance Spectroscopy 7enfortumab vedotin 5Nivolumab 5Ipilimumab 4Gemcitabine 4Cisplatin 3CTLA-4 Antigen 3sacituzumab govitecan 2Taxes 2Paclitaxel 2Mitomycin 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2tislelizumab 1temsirolimus 1tazemetostat 1sapanisertib 1relatlimab 1lenvatinib 1eribulin 1erdafitinib 1durvalumab 1cabozantinib 1belinostat 1atezolizumab 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Cell Count × 30 days × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡